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Abstract
Methods for standard meta-analysis of diagnostic test accuracy studies are well
established and understood. For the more complex case in which studies report
test accuracy across multiple thresholds, several approaches have recently been
proposed. These are based on similar ideas, but make different assumptions. In
this article, we apply four different approaches to data from a recent systematic
review in the area of nephrology and compare the results. The four approaches
use: a linear mixed effects model, a Bayesianmultinomial random effects model,
a time-to-eventmodel and a nonparametricmodel, respectively. In the case study
data, the accuracy of neutrophil gelatinase-associated lipocalin for the diagno-
sis of acute kidney injury was assessed in different scenarios, with sensitivity
and specificity estimates available for three thresholds in each primary study. All
approaches led to plausible and mostly similar summary results. However, we
found considerable differences in results for some scenarios, for example, differ-
ences in the area under the receiver operating characteristic curve (AUC) of up
to 0.13. The Bayesian approach tended to lead to the highest values of the AUC,
and the nonparametric approach tended to produce the lowest values across the
different scenarios. Thoughwe recommend using these approaches, our findings
motivate the need for a simulation study to explore optimal choice of method in
various scenarios.
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1 INTRODUCTION
Diagnostic tests are often based on biomarkers, psychiatric scales, or risk scores that are measured on a continuous, dis-
crete, or ordinal scale. These tests can be implemented at varying diagnostic thresholds (i.e. value such that results, say,
greater than or equal to the threshold are called ‘positive’ and those less than the threshold ‘negative’). The aim of diag-
nostic test accuracy (DTA) studies is to estimate the accuracy of such diagnostic tests. In systematic reviews, the results
from two or more DTA studies are combined. In a primary DTA study, each individual provides two pieces of infor-
mation: their test value (on any scale) and their true disease status (with/without the target condition, for example, a
disease, herein referred to as ‘diseased’ and ‘disease-free’), which is usually assumed to be measured without error by a
reference or ‘gold standard’ test. All individuals in a study together therefore provide empirical distributions of test val-
ues in each disease group. However, instead of reporting the individual values or distributions, publications of primary
studies usually report only a few two-by-two tables, or pairs of sensitivity (true positive fraction) and specificity (true
negative fraction) corresponding to a small number of thresholds. Researchers also often display receiver operating char-
acteristic (ROC) curves, which are plots of sensitivity against 1 − specificity across all possible thresholds, and/or the
area under the ROC curve (AUC). For an overview of these and further diagnostic accuracy measures, see, for example,
Eusebi (2013).
There are well-established methods for meta-analysis of DTA, namely the hierarchical summary receiver operating
characteristic curve model proposed by Rutter and Gatsonis (2001) and the bivariate model proposed by Reitsma et al.
(2005) and amended by Chu and Cole (2006). These approaches are fully equivalent if no covariates are considered (Har-
bord, Deeks, Egger, Whiting, & Sterne, 2007). Though both models allow for heterogeneity and correlation resulting from
variation in threshold across studies, they do not use the actual numerical values of these thresholds. This means it is
unknown what threshold value any pooled estimate (or point on the summary ROC curve) corresponds to. Further, these
approaches can only accommodate a single two-by-two table (i.e. test accuracy measures at a single threshold) from each
study, whereas primary studies often report at multiple thresholds. Choosing just one of these pairs of data to input into
the meta-analysis would lead to a heavy loss of information (Trikalinos et al., 2012).
Whereas the Cochrane Handbook for DTA Reviews currently recommends using standard meta-analysis methodol-
ogy separately for each reported threshold (Macaskill, Gatsonis, Deeks, Harbord, & Takwoingi, 2010), more advanced
and specialized statistical methods to address these issues through a unified analysis are now available. There are many
approaches for the analysis of full ROC curves. However, we have not considered those with relevant limitations, such
as, for example, the requirement of identical thresholds across studies (for a detailed discussion, see Hoyer, Hirt, & Kuss,
2018) and have therefore chosen the approaches from Hoyer et al. (2018), Jones, Gatsonsis, Trikalinos, Welton, and Ades
(2019), Frömke, Kirstein, and Zapf (2020), and Steinhauser, Schumacher, and Rücker (2016). The desirability of such
approaches has also been expressed in a Cochrane review (Heazell et al., 2019) and in a recent simulation study (Vogelge-
sang, Schlattmann, & Dewey, 2018).
These more advanced approaches all view the problem from the following perspective: in each study, test results have
different distributions among diseased and disease-free persons. The cumulative distribution function (cdf) of test results
in the disease-free individuals defines the specificities across the full range of possible thresholds, while the cdf in the
diseased individuals defines the full range of false negative fractions ( = 1 – sensitivities). The task of a meta-analysis
of DTA studies is to use the available data to estimate a ‘summary’ cdf in each of the two populations, which provides
summary sensitivities and specificities across a sensible range of thresholds.
The starting point for this article was a data challenge on the dataset used here (see Section 2) at a conference. The
aim of the data challenge was to apply four such approaches to a case study dataset and to compare the results. We found
that results were quite heterogeneous. We wanted to share this knowledge first and then systematically investigate it in
a second step by means of a simulation study (see Sections 5 and 6). In the following section the case study data and the
underlying medical question are explained. After giving an overview of the individual approaches in Section 3, the results
are presented in Section 4 and discussed in Section 5. We finish with some concluding remarks and suggested next steps.
2 CASE STUDYMETA-ANALYSIS
The case study meta-analysis comes from the field of nephrology. The aim was to evaluate the diagnostic accuracy of neu-
trophil gelatinase-associated lipocalin (NGAL) as a test for acute kidney injury (AKI). Haase-Fielitz, Haase, andDevarajan
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TABLE 1 Number of primary studies in the different scenarios
Sampling material AKI Severe AKI RR
Plasma 18 16 12
Urine 12 10 9
(2014) systematically reviewed the utility of NGAL for the diagnosis of AKI. The review found 58 relevant articles overall,
and the authors calculated raw (un-weighted) mean sensitivity and specificity across all studies in each clinical setting
(cardiac surgery versus critical care/emergency department) and with urine and blood as sampling material. Despite this
consideration of influencing factors, the results were extremely heterogeneous (within one scenario study-specific AUC
values varied between 0.50 and 0.99). The authors identified variation in thresholds and in reference standard (based on
different AKI definitions) as key potential reasons for heterogeneity. Therefore, Albert et al. (2020b) conducted a succes-
sional meta-analysis, contacted the authors of identified primary studies and asked for additional information and data
to allow exploration of this. The authors of 26 primary studies responded and provided 30 reassessed datasets. The quality
assessment using the QUADAS-2 tool (Whiting et al., 2011) demonstrated overall a low risk of bias and high applicability
(Albert et al., 2020b).
Using a consensus AKI definition based on the RIFLE criteria (risk, injury, failure, loss, end-stage renal disease), three
event types were distinguished: AKI, severe AKI and renal replacement therapy (RRT). Whereas the outcome measures
AKI and severe AKI are based on consensus classification criteria (Bellomo, Ronco, Kellum, Mehta, & Palevsky, 2004),
the assessment of RRT as outcome measure is limited by the absence of a consented gold standard on whether and when
to initiate RRT. Therefore, clinical practice variability may contribute to pronounced variability of thresholds (Klein et al.,
2018). Data were stratified by these three alternative ‘reference standards’, which can clearly be expected to lead to dif-
ferences in estimates of sensitivity and specificity. Some studies provided data relating to two or three of these reference
standards. Data were also stratified by whether NGAL was measured in urine or in blood (in the following, referred to as
sampling material). In secondary analyses, the effect of the clinical setting (see above) and of the use or non-use of the
urine output criteria for the assessment of the AKI stage was investigated. However, these secondary analyses will not be
considered here. Therefore, in total we consider six separate but related datasets: the number of contributed individual
datasets according to each endpoint is displayed in Table 1. Our meta-analyses for these six scenarios were performed
separately.
For each primary study, sensitivity and specificity estimates were requested and provided for three different thresholds:
such that (1) the estimated sensitivity is at least 95%; (2) the estimated specificity is at least 95%; and (3) the estimated sum
of sensitivity and specificity is maximized (Youden criterion for ‘optimal’ threshold; Schisterman & Perkins, 2007). NGAL
levels peak approximately 6 h after kidney tubular injury and followed a dose–response curve with respect to severity of
injury (Haase-Fielitz et al., 2009;Mishra et al., 2005). Accordingly, the thresholds for which data were provided had a wide
range (up to 10,000 ng/mL), independently of the event type, since a specific number of patients included in the outcome
measure ‘severe AKI’ overlap with ‘AKI’ and to a lesser extend with ‘RRT’. Albert et al. (2020b) found that the median
threshold were lower for urine than for plasma and all threshold concentrations increased with increasing AKI severity
or requirement of RRT. Figure 1 shows weighted NGAL threshold concentrations separately for the endpoints and sample
materials. The number of outliers was low and represented studies with low patient numbers.
3 METHODS
In this section, the different approaches are briefly summarized; for full details we refer to the original publications. As
far as possible we use a common notation for all approaches.
3.1 Notation
We index the studies in each dataset by 𝑘 = 1,… ,𝑁 and the true disease state by 𝑑 = 0 (disease-free individuals) and
𝑑 = 1 (diseased individuals). In study 𝑘, status group 𝑑, there are 𝑛𝑘𝑑 participants. We index these individual study
participants by 𝑠 = 1,… , 𝑛𝑘𝑑. The actual continuous test result of participant 𝑠 in status group 𝑑 in study 𝑘 is denoted by
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F IGURE 1 Distribution of the thresholds (in ng/mL) at which data were provided across studies, for the three endpoints and three criteria
for plasma (left panel) and urine (right panel). Each boxplot includes the number of contributing studies (see Table 1). the right panel, four
extreme values are not displayed: 4742 and 7445 for AKI, 7445 also for severe AKI, and 9453 for RRT (all for the criterion of 95% specificity)
𝑋𝑘𝑑𝑠. We index the thresholds at which data are available in study 𝑘 by 𝑖 = 1, … , 𝑡𝑘 (where 𝑡𝑘 = 3 for all 𝑘 in the present
case study) and denote the numerical threshold values that these correspond to by 𝑐𝑘𝑖 .
The sensitivity (𝑠𝑒) is equivalent to the true positive fraction (𝑡𝑝𝑓), while the specificity (𝑠𝑝) is equivalent to the true
negative fraction (𝑡𝑛𝑓), leading accordingly to 1 − 𝑠𝑝 as the equivalent of the false positive fraction (𝑓𝑝𝑓). Further, we
use the definition of the logit function logit(𝑥) = log(𝑥) − log(1 − 𝑥).
3.2 The random effects model by Steinhauser et al. (2016)
The model by Steinhauser is a two-stage random effects model. At the study level, for each (in the present study log-
transformed) value of the threshold, the observed (true or false) negative fraction is transformed using a suitable quantile
function 𝑓 (in the present study, the logit function). At the meta-analysis level, a linear mixed effect model is fitted to
the resulting values across studies. The model used in this study (originally called DIDS*, standing for Different random





= %𝛼0 + %𝑎0𝑘 + (𝛽0 + %𝑏0𝑘) log(𝑐𝑘𝑖) + %𝜖𝑘𝑖
logit (1 − ŝeki) = 𝛼1 + 𝑎1𝑘 + (𝛽1 + 𝑏1𝑘) log (𝑐ki) + 𝛿ki.
Here, the logit transformation in combination with log-transforming the threshold values (𝑐𝑘𝑖) corresponds to the
assumption of underlying log-logistic distributions for 𝑋𝑘0𝑠 and 𝑋𝑘1𝑠. Here 𝑠𝑝𝑘𝑖 and 𝑠𝑒𝑘𝑖 denote the crude estimates of
(i.e. observed values of) specificity and the sensitivity at threshold 𝑐𝑘𝑖 in study 𝑘, 𝛼0 and 𝛼1 are fixed intercepts, and 𝛽0
and 𝛽1 are fixed slopes for the disease-free and the diseased individuals, respectively. The terms 𝑎0𝑘, 𝑎1𝑘, 𝑏0𝑘, 𝑏1𝑘 denote
random intercepts and slopes, which are assumed to follow a common four-dimensional normal distribution, that is, to
be correlated across studies, and ∈ki and δki represent within-study random errors. Each data point is weighted with the
inverse variance of the respective logit-transformed proportion. Back-transformation of the fixed effects part of the model
equations provides the model-based distribution functions for disease-free and diseased individuals, fromwhich amodel-
based summary ROC curve with pointwise confidence regions is obtained. The area under the curve (AUC) is obtained
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by numerical integration based on the trapezoidal rule. An optimal threshold, defined as a threshold where the Youden
index is maximized, is identified as the point where the densities intersect.
The model was implemented in the R package diagmeta (Rücker, Steinhauser, Kolampally, & Schwarzer, 2018) in the
free software environment R (R Development Core Team, 2008). For more details of the modelling, we refer to the original
article (Steinhauser et al., 2016).
3.3 The Bayesian model by Jones et al. (2019)
Jones et al. (2019) propose a Bayesianmodel withmultinomial likelihoods and (similarly to Steinhauser et al., 2016, DIDS*
model, described above) four sets of random effects. Study-specific estimates of sensitivity and specificity are first used to
derive the number of test results in each of the diseased and disease-free populations that fell below the lowest threshold
𝑐𝑘1, between each pair of thresholds 𝑐𝑘𝑖 and 𝑐𝑘𝑖+1 (for 𝑖 = 1, … , 𝑡𝑘−1), and above the highest threshold 𝑐𝑘𝑡𝑘 . That is, test
results are categorized into 𝑡𝑘 + 1 (= 4 for each study 𝑘, in this case study) groups, in each of the diseased and disease-free
groups. A multinomial likelihood is assumed for each set of four values.
We denote the underlying true and false positive fractions at the 𝑖th threshold in study 𝑘 by 𝑡𝑝𝑓𝑘𝑖 and 𝑓𝑝𝑓𝑘𝑖 . Themodel
specifies that
logit (𝑓𝑝𝑓𝑘𝑖) =
𝜇𝑘0 − 𝑔 (𝑐𝑘𝑖)
𝜎𝑘0
logit (𝑡𝑝𝑓𝑘𝑖) =
𝜇𝑘1 − 𝑔 (𝑐𝑘𝑖)
𝜎𝑘1
,
where 𝑔() is a function that transforms test results in the disease-free population to approximately Logistic(𝜇𝑘0, 𝜎𝑘0) and
test results in the diseased population to approximately Logistic (𝜇𝑘1, 𝜎𝑘1), where 𝜇𝑘𝑑 and 𝜎𝑘𝑑 are mean and scale param-
eters in status group 𝑑. For example, if 𝑔() is the natural logarithm, this corresponds to assuming log-logistic distributions
for test results in each status group (in common with the Steinhauser et al., 2016, model, as described above).
Jones et al. (2019) demonstrate that it is not necessary to pre-specify the transformation function, 𝑔(): we can assume
simply that 𝑔() is in the set of Box–Cox transformation functions and estimate the Box–Cox transformation parameter
from the data. Computation time is substantially reduced if 𝑔() can be pre-specified, however. In this case study, we fitted
two versions of the model to each of the six datasets: (i) with 𝑔() set to the natural logarithm, (ii) the extended version
in which the Box–Cox transformation parameter, 𝜆, is estimated. A value of 𝜆 = 0 corresponds to 𝑔() = log(). In this
paper, we present results from the extended version of the model if the 95% credible interval around 𝜆 did not include 0,
and results from the 𝑔() = log() model otherwise. For one of the six analyses (AKI measured in plasma), the extended
version of the model did not converge; so we present the 𝑔() = log() results.
The model assumes four sets of normally distributed random effects: 𝜇𝑘0, 𝜇𝑘1, log(𝜎𝑘0), log(𝜎𝑘1), thereby allowing for
heterogeneity across studies in both the ‘average’ and spread of test results in the diseased and disease-free populations. A
quadrivariate normal distribution can be fitted to these.11 However, in two previous case studies, Jones et al. (2019) found
no benefit in terms of model fit (after penalizing for complexity) from doing so, relative to treating the four sets of random
effects as independent. In this paper, we show results from this simplified version of the model only.
The AUC is calculated by simulation within the model code as the probability that 𝑦1 ≥ 𝑦0, where 𝑦1 and 𝑦0 are logistic
distributions with means and log-scale parameters set at the means of the random effects. The model was implemented
in WinBUGS (Lunn, Thomas, Best, & Spiegelhalter, 2000), and the code is available in Jones et al. (2019).
3.4 The time-to-event model by Hoyer et al. (2018)
The central assumption of the model proposed by Hoyer et al. (2018) is that diagnostic test values can be considered as
interval-censored as we only know if these test values (and howmany of them) lie above or below a predefined threshold.
For modelling these interval-censored diagnostic test values in the diseased and disease-free populations, three different
distributions are assumed: the Weibull, log-normal and log-logistic distribution. In line with the class of time-to-event
models, the ‘events’ of interest are testing positive or negative in the diseased or disease-free populations, respectively.
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Furthermore, the diagnostic test values are considered as a ‘timescale’. Consequently, sensitivity is our event probability
in the diseased population (and, vice versa, 1-specificity in the disease-free population). To arrive at an accelerated failure
time model with a unified linear predictor, the outcome, that is the diagnostic test values, are log-transformed. The final
model equations are then
log (𝑥𝑘0) = 𝑏0 + 𝜀0 + 𝑢𝑘0



















where 𝑏1 and 𝑏0 are location parameters after log-transforming the outcome, whereas 𝜀1 and 𝜀0 are error terms with dis-
tributions of the log-transformed diagnostic test values 𝑥𝑘1 and 𝑥𝑘0 of the diseased and disease-free populations, respec-
tively. Study-specific random effects 𝑢𝑘1 and 𝑢𝑘0 are assumed to have a bivariate normal distribution with variances 𝜎20
and 𝜎21 and correlation parameter 𝜌. These random effects are added to the location parameters after log-transformation
and are used to account for between-study heterogeneity and potential between-study correlations. Note there are only
two sets of random effects, rather than four in the Steinhauser et al. (2016) and Jones et al. (2019) models. Finally, the
resulting survival functions are used to predict sensitivities and specificities at several thresholds.
Results shown in this article are based on the assumption of an underlyingWeibull distribution for 𝑋𝑘0 and𝑋𝑘1, as this
version of the model performed best in simulation studies (Hoyer et al., 2018).
The model was implemented in SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Corresponding source code is available
in Hoyer et al. (2018).
3.5 The nonparametric model by Frömke et al. (2020)
Rather than assuming parametric distributions of test results in the diseased and disease-free groups (as each of the three
approaches described above does), the approach proposed by Frömke et al. (2020) is nonparametric, that is does not require
any assumptions about distributions. The approach is an extension of a nonparametric method proposed for analysis of
diagnostic studies with repeated measures (Brunner & Zapf, 2013; Konietschke & Brunner, 2009) to a meta-analysis of
diagnostic accuracy studies with multiple thresholds (Frömke et al., 2020).
The AUC is equal to the relative effect 𝑝 = 𝑃(𝑋𝑘0𝑠 < 𝑋𝑘1𝑠) +
1
2
𝑃( 𝑋𝑘0𝑠 = 𝑋𝑘1𝑠 ). To estimate the AUC, all measure-
ments 𝑋𝑘𝑑𝑠 are replaced by their global mid-ranks 𝑅𝑘𝑑𝑠 and the mean rank ?̄?.𝑑. is calculated of all individuals with status












𝑛𝑘𝑑 is the total number of diseased and disease-free participants
across all studies. Instead of individual patient data 𝑋𝑘𝑑𝑠, needed for the calculation of the ranks, only aggregate infor-
mation is available. However, for each study, the number of diseased and disease-free individuals less or greater than the
study-specific thresholds 𝑐𝑘𝑖 is known. Based on this information, we generated data from a one-point distribution, such
that 𝑋𝑘𝑑𝑠 = 𝑐𝑘1 − 1 for all
𝑋𝑘𝑑𝑠 < 𝑐𝑘1, 𝑋𝑘𝑑𝑠 =
(𝑐𝑘𝑖+𝑐𝑘𝑖+1)
2
if 𝑐𝑘𝑖 < 𝑋𝑘𝑑𝑠 < 𝑐𝑘𝑖+1 with (for 𝑖 = 2, … , 𝑡𝑘−1), and 𝑋𝑘𝑑𝑠 = 𝑐𝑘𝑡𝑘 + 1 for all 𝑋𝑘𝑑𝑠 > 𝑐𝑘𝑡𝑘 .
For a specific threshold, sensitivity and specificity are estimated in the sameway as the AUC, but with transformed data.
In order to estimate the sensitivity, the observations of the disease-free individuals are replaced by a one-point distribution
at the chosen threshold. Likewise, specificity is obtained by replacing the observations of the individuals with the disease
by a one-point distribution (Lange & Brunner, 2012). By means of the asymptotic equivalence theorem, it can be shown
that
√
𝑁(?̂? − 𝑝) ∼ 𝑁(0, 𝜎2). Therefore, the standard Wald confidence interval for the AUC as well as for sensitivity and
specificity can be computed.Applying the logit transformation to the confidence interval, the limits staywithin the interval
[0, 1].
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AKI Plasma 0.75 0.81 0.75 0.68
Urine 0.69 0.74 0.63 0.65
Severe AKI Plasma 0.77 0.81 0.80 0.77
Urine 0.74 0.79 0.69 0.73
RRT Plasma 0.84 0.86 0.87 0.86
Urine 0.76 0.82 0.72 0.71
TABLE 3 Variation between the four approaches, depending on the scenario (AKI/severe AKI/RRT and sampling material




95% sensitivity Maximum Youden index 95% specificity























































































Themodel was implemented in in the free software environment R (R Development Core Team, 2008) and correspond-
ing source code is available in Frömke et al. (2020).
4 RESULTS
It should be noted in advance that the results in the article by Albert et al. (2020b) differ from the results in this article
because these authors used the log-normal distribution, whereas we use the Weibull distribution. The individual ROC
curves and summary ROC curves resulting from the different approaches are illustrated for all scenarios in Figure 2
(including the confidence region of the Steinhauser model) and in Figure 3 (including the individual ROC curves). Even if
the curves are partly quite different, it is noticeable that the confidence region of the Steinhauser model includes all other
curves almost completely (NB: no confidence regions can be given for the other models). The differences regarding the
curves are also reflected in the corresponding AUCs, which are provided for all six scenarios in Table 2. The differences in
AUCs for NGAL measured in plasma range from 0.04 for severe AKI and RRT to 0.13 for AKI. The Jones et al. approach
(2019) tended to lead to the highest values of AUC, and the Frömke et al. approach (2020) to the lowest values.
The entire results are given in the Supporting Information (Table A1–A3), with a summary provided in Table 3, which
shows that these results sometimes differed considerably acrossmethods. For the criterion of 95% sensitivity, the threshold
and the estimated specificity of the four approaches were quite similar for plasma and urine for the endpoints AKI and
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F IGURE 2 Summary ROC curves of the four approaches in the six scenarios and the confidence region for the Steinhauser model as grey
area. The pairs of sensitivity and 1 – specificity of the individual studies are displayed as grey dots
severe AKI. For the endpoint of RRT, the threshold and therefore also the estimated specificity was considerably higher
than for AKI and severe AKI.
The estimated summary sensitivity and specificity to maximize the Youden index were quite similar across methods
for AKI and severe AKI, as well as for NGAL measured in urine and in plasma. Thresholds were lower for urine than
for plasma. The variability across methods was quite small regarding the threshold as well as estimated sensitivity and
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F IGURE 3 Summary ROC curves of the four approaches in the six scenarios and the ROC curves of the individual studies as grey lines
specificity for severe AKI and NGAL measured in plasma. However, for RRT as the endpoint and NGAL measured in
plasma, the variabilitywas remarkably high, and also the estimated sensitivity and specificitywere higher than in the other
scenarios. Regarding the criterion of 95% specificity, the variability in thresholds was very high. The estimated sensitivity
was in the same range for AKI plasma, severe AKI urine and plasma and RRT urine, but remarkably higher for RRT
plasma.
10 ZAPF et al.
5 DISCUSSION
In this paper, we presented, compared and applied four recently proposed approaches to meta-analyse data from DTA
studies providing information on sensitivity and specificity at several thresholds. All four approaches use the full data
from these studies and thus are promising additions to the toolbox of meta-analysis of DTA studies.
As an example, we showed results from applying each approach to data evaluating the diagnostic accuracy of NGAL as a
test for AKI. From amedical point of view, the results of our case study can be summarized as follows: The relatively large
differences between the lowest and the highest AUC estimates in the presented approaches (0.68–0.81 for AKI measured
in plasma) may translate into withholding or not withholding diagnostic or therapeutic measures (Albert et al., 2018,
2020a). A biomarkers applicability as a screening test will call for high sensitivity. For the corresponding criterion of at
least 95% sensitivity, the result was (across all fourmeta-analysis methods) an estimated specificity below 30% for AKI and
severe AKI. For RRT, the estimated specificity was higher, but quite different between the analysis approaches (23–63% for
plasma, 22–48% for urine). From a statistical point of view, in our case study we found considerable differences between
the approaches in summary results for some data scenarios.
While Jones et al. (2019), Steinhauser et al. (2016), and Hoyer et al. (2018) are parametric approaches, the approach
from Frömke et al. (2020) is a non-parametric one. The three parametric approaches make different assumptions about
the distributional form of the underlying test values. As applied in this article, the model of Steinhauser et al. (2019)
assumes log-logistic distributions, although alternatively an assumption of logistic, log-normal or normal distributions
is possible. The model of Jones et al. (2019) assumes some Box–Cox transformation of continuous test results (e.g. log),
where the Box–Cox transformation does not need to be pre-specified. In this paper, for the model of Hoyer et al. (2018) a
Weibull distribution is assumed, but alternatively it is possible to assume log-normal or log-logistic distributions within
the Hoyer framework. Other differences include the number of random effects (4 or 2), the choice of parameters that are
random effects (which are not linear functions of each other) and the likelihoods (normal or multinomial) (see also Jones
et al., 2019). A summary of some of the characteristics of the four approaches is provided in Table 4.
For the original analysis presented in Albert et al. (2020a), the model of Hoyer et al. (2018) assuming a log-normal
distribution was applied. Slight differences between results given in the present article and the original publication are
caused by varying distributional assumptions. However, confidence intervals of estimated sensitivities, specificities and
AUC overlap each other, indicating that there is no evidence for a difference between them.We decided to use theWeibull
distribution in this article because it performed best in simulation studies compared to other distributions (Hoyer et al.,
2018).
Our case study dataset is a real-life example that highlights that it may be difficult for analysts to choose between
the recently published approaches. No systematic comparison of the approaches has been published so far. A limitation
of our analysis is that not all possible approaches have been included. However, the other proposed approaches each
have specific disadvantages, such that their general applicability is more limited. Several of these models rely on each
study reporting data at an identical number of thresholds (Bipat, Zwinderman, Bossuyt, & Stoker, 2007; Hamza, Arends,
Van Houwelingen, & Stijnen, 2009; Poon, 2004; Putter, Fiocco, & Stijnen, 2010). Other approaches ignore the precise
threshold values (Dukic & Gatsonis, 2003; Martinez-Camblor, 2017) or are fixed-effect models (Riley et al., 2014). Due to
their disadvantages, we decided to not include these models in the present case study. We instead used only approaches
that can cope with the features of the underlying dataset and, in addition, do not require the same number of thresholds.
We note that our case study data were somewhat artificial, with the same number of thresholds and same requirement
for each threshold (that gave 95% sensitivity, 95% specificity, andmaximized the Youden index, respectively) in all primary
studies. This specific setting resulted from the original study’s aim to identify urinary and plasma NGAL cut-off concen-
trations with high sensitivity or high specificity to complement the identification of patients at high kidney risk in clinical
research and practice (Albert et al., 2020b, 2021).
In practice, primary studies in a systematic review may report at varied numbers of thresholds and perhaps with even
more variability in threshold values.
In this article, the events AKI, severe AKI and RRT were analysed separately. An alternative approach would be to
define the true state not dichotomously but in the form of a four-level score (no AKI, AKI, severe AKI, RRT). However,
none of the four approaches investigated here is suitable for such an analysis.
Based on just one case study dataset, we cannot identify the reasons for the differences in summary results across
methods or generalize our results to other datasets, although we have discussed some of the features that vary across
the approaches. Nevertheless, given that standard approaches to meta-analysis of DTA data across multiple and varying
ZAPF et al. 11










Aggregated data sufficient X X X X
One-step approach X X
Zero cells allowed (X)a X X X







































Measure of heterogeneity (like 𝐼b) regarding
diagnostic accuracy / thresholds





Inclusion of study-level covariates possible
(i.e. meta-regression)
X X
aIn the case of zero cells, a continuity correction is necessary.
bThresholds are presented with confidence intervals, if the normal transformation is used, but not for the logit transformation.
thresholds lead to a heavy loss of information and likely biased results (see Introduction), we recommend using one of
the presented approaches for data of this type.
In a recent study by Benedetti et al. (2020), in which the results of meta-analyses based on published and on individual
level data were compared, the differences between the models from Steinhauser and Jones were much smaller. The ques-
tion therefore arises whether the differences detected here might be due to some peculiarities specific to our case study
dataset. In addition, it can be seen that the confidence region of the Steinhauser model almost completely includes the
other summary ROC curves, so that it cannot be excluded that the differences are simply due to random error. The differ-
ences regarding themodel from Frömke are perhaps driven by the use of ranks instead of original observations. Therefore,
this approach is insensitive to outliers.
To assess which approach can be recommended inwhich situation, we are currently conducting a systematic simulation
study.We are investigating the effect of a number of factors, including the true distributions of the test results, the number
of studies and thresholds, and the effect of any outliers. We hope that the results observed in the present case study may
then be explained.
6 CONCLUSION
We compared four existing statistical approaches to analyse multiple-threshold information from DTA studies by
applying them to a real-life meta-analysis of the diagnostic accuracy of NGAL for the detection of acute kidney injury
with three thresholds per study. The results show quite large heterogeneity of the approaches in some data scenarios,
with differences in estimated AUC of up to 0.13. However, all summary ROC curves lie within the confidence region of
the Steinhauser model and therefore the differences are perhaps only random variations. We recommend use of these
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approaches in practice. However, at this stage it is unclear which approach should be preferred in any given situation.
Therefore, currently a simulation study is conducted to investigate the advantages and limitations of the different
approaches. However, this case report makes aware that the results one gets – and this is true for most statistical analyses
– are not the final truth. This, in turn, makes it clear how important it is to pre-specify methods that readers can be
confident the method was not chosen based on results.
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